Sanofi offer suggests value in Lemtrada, but not much
This article was originally published in Scrip
Just over a week after Sanofi received a US FDA refuse-to-file letter on 27 August for its multiple sclerosis drug Lemtrada (scripintelligence.com 27 August 2012), the company has offered a premium price to buy the Contingency Value Rights associated with its 2011 purchase of Genzyme. This suggests that Sanofi wants to signal strongly to both its own shareholders and to CVR holders that Lemtrada's (alemtuzumab) problems are resolvable. At the same time, the company may be trying to test investors' perceptions of Lemtrada's prospects in MS in order to calculate how to minimise its outlay on the CVRs in the following months and years.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.